Literature DB >> 34059196

Von Willebrand disease combined with coagulation defects in Iran.

Omid Seidizadeh1, Minoo Ahmadinejad2, Sanaz Homayoun2, Pier Mannuccio Mannucci1, Flora Peyvandi1,3.   

Abstract

BACKGROUND: Although Von Willebrand disease (VWD) is the most common inherited bleeding disorder, few cases of VWD combined with coagulation defects have been reported. This study sought to determine the clinical and laboratory features of VWD combined with other coagulation defects and to evaluate the prevalence of this combination in Iran.
MATERIAL AND METHODS: A total of 3,120 cases were evaluated to confirm a suspected diagnosis of VWD. Clinical and laboratory phenotypes, including bleeding scores (BS), were also obtained.
RESULTS: A diagnosis of VWD was established for 130 patients. Following their further characterisation, a subgroup of 25 patients with a dual or triple combination of VWD with coagulation defects (FXII, FXI, FIX, FVII, FV, and lupus anticoagulant) was identified. Their laboratory and clinical data were compared with those of healthy controls (n=25) and VWD-only patients (n=25). No differences were observed for VWF-related laboratory measurements between the combined deficient cases and those with VWD only, results being expectedly lower than in healthy controls. The median BS of combined patients was 4, higher than for VWD-only and control groups (median BS 3 and 1; p=0.55 and p<0.001, respectively). DISCUSSION: The prevalence of combined coagulation defects was 19.2% among all the VWD cases. The co-occurrence of VWD with clotting factor deficiencies may lead to more severe clinical presentations. To ensure adequate treatment, combined defects should be considered in VWD patients presenting with a more severe bleeding phenotype than expected or with a poor response to treatment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34059196      PMCID: PMC8486600          DOI: 10.2450/2021.0078-21

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  18 in total

1.  Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Authors:  V Pengo; A Tripodi; G Reber; J H Rand; T L Ortel; M Galli; P G De Groot
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

2.  Combined von Willebrand disease and Hageman factor deficiency.

Authors:  G R Buchanan; D M Green; R I Handin
Journal:  J Pediatr       Date:  1977-05       Impact factor: 4.406

3.  Combined clotting factor deficiencies: experience at a single hemophilia treatment center.

Authors:  S H O'Brien; A K Ritchey; M V Ragni
Journal:  Haemophilia       Date:  2007-01       Impact factor: 4.287

4.  Combined severe factor XI deficiency and von Willebrand's disease.

Authors:  J Chediak; E Lambert; E I Johnson; M C Telfer
Journal:  Am J Clin Pathol       Date:  1980-07       Impact factor: 2.493

5.  Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease.

Authors:  M Lak; F Peyvandi; P M Mannucci
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 6.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

7.  Epidemiological investigation of the prevalence of von Willebrand's disease.

Authors:  F Rodeghiero; G Castaman; E Dini
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

8.  Bleeding manifestations in males with von Willebrand disease.

Authors:  O Ziv; M V Ragni
Journal:  Haemophilia       Date:  2004-03       Impact factor: 4.287

9.  Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project.

Authors:  M Elbatarny; S Mollah; J Grabell; S Bae; M Deforest; A Tuttle; W Hopman; D S Clark; A C Mauer; M Bowman; J Riddel; P A Christopherson; R R Montgomery; M L Rand; B Coller; P D James
Journal:  Haemophilia       Date:  2014-09-06       Impact factor: 4.287

10.  ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease.

Authors:  Paula D James; Nathan T Connell; Barbara Ameer; Jorge Di Paola; Jeroen Eikenboom; Nicolas Giraud; Sandra Haberichter; Vicki Jacobs-Pratt; Barbara Konkle; Claire McLintock; Simon McRae; Robert R Montgomery; James S O'Donnell; Nikole Scappe; Robert Sidonio; Veronica H Flood; Nedaa Husainat; Mohamad A Kalot; Reem A Mustafa
Journal:  Blood Adv       Date:  2021-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.